BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+14.45%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$128M
AUM Growth
+$128M
(+8.6%)
Cap. Flow
+$4.59M
Cap. Flow
% of AUM
3.59%
Top 10 Holdings %
Top 10 Hldgs %
70.42%
Holding
59
New
8
Increased
11
Reduced
8
Closed
1
Top Buys
| 1 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$1.43M |
| 2 |
Phreesia
PHR
|
$741K |
| 3 |
Stoke Therapeutics
STOK
|
$658K |
| 4 |
10x Genomics
TXG
|
$504K |
| 5 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$366K |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$836K |
| 2 |
Bristol-Myers Squibb
BMY
|
$718K |
| 3 |
BLUE
bluebird bio
BLUE
|
$185K |
| 4 |
TSVT
2seventy bio
TSVT
|
$171K |
| 5 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$122K |
Sector Composition
| 1 | Healthcare | 95.37% |
| 2 | Energy | 4.62% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $36M | 28.19% | 702,298 -13,999 | -2% | -$718K |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $10.2M | 7.96% | 77,240 | – | – |
|
3
Biodesix
BDSX
$62.6M
| $9.79M | 7.66% | 5,348,273 | – | – |
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $7.53M | 5.89% | 240,400 | – | – |
|
5
Prothena Corp
PRTA
$441M
| $6.16M | 4.82% | 169,574 | – | – |
|
|
IMGN
6
DELISTED
Immunogen Inc
IMGN
| $5.57M | 4.36% | 188,000 -2,000 | -1% | -$59.3K |
|
7
QuidelOrtho
QDEL
$1.95B
| $4.81M | 3.76% | 65,203 | – | – |
|
8
Ovintiv
OVV
$10.8B
| $3.7M | 2.89% | 84,200 | – | – |
|
9
Elutia
ELUT
$96.7M
| $3.58M | 2.8% | 1,655,184 | – | – |
|
|
10
Phreesia
PHR
$1.88B
| $2.66M | 2.08% | 114,700 +32,000 | +39% | +$741K |
|
11
United Therapeutics
UTHR
$13.8B
| $2.42M | 1.89% | 11,000 | – | – |
|
12
Cytokinetics
CYTK
$4.23B
| $2.09M | 1.63% | 25,000 | – | – |
|
13
Foghorn Therapeutics
FHTX
$286M
| $2.07M | 1.62% | 320,930 +56,087 | +21% | +$362K |
|
|
SILK
14
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $1.94M | 1.52% | 158,094 +116,800 | +283% | +$1.43M |
|
|
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.84M | 1.44% | 48,448 -22,000 | -31% | -$836K |
|
16
Masimo
MASI
$7.59B
| $1.79M | 1.4% | 15,280 | – | – |
|
17
Harrow
HROW
$1.44B
| $1.68M | 1.31% | 150,000 | – | – |
|
|
18
10x Genomics
TXG
$1.74B
| $1.68M | 1.31% | 30,000 +9,000 | +43% | +$504K |
|
19
Corcept Therapeutics
CORT
$7.35B
| $1.62M | 1.27% | 50,000 | – | – |
|
20
Alkermes
ALKS
$4.78B
| $1.39M | 1.09% | 50,000 | – | – |
|
|
ETRN
21
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.35M | 1.06% | 133,050 | – | – |
|
22
Alphatec Holdings
ATEC
$2.35B
| $1.33M | 1.04% | 88,000 +8,000 | +10% | +$121K |
|
23
Axogen
AXGN
$743M
| $1.18M | 0.92% | 173,000 | – | – |
|
|
24
Stoke Therapeutics
STOK
$1.08B
| $1.1M | 0.86% | 210,000 +125,000 | +147% | +$658K |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $1.1M | 0.86% | 48,000 +10,000 | +26% | +$229K |
|